Literature DB >> 7832104

Rest technetium 99m-sestamibi tomoscintigraphy in hibernating myocardium.

J C Maublant1, B Citron, J Lipiecki, D Mestas, P Bailly, A Veyre, C de Riberolles, J Ponsonnaille.   

Abstract

The myocardial uptake of rest-injected technetium 99m sestamibi on single-photon-emission computed tomographic images was assessed in 25 patients. All had an area of myocardial dysfunction that could be related to a coronary artery stenosis. None of the patients had clinical evidence of a myocardial infarction. Three months after revascularization, viability was demonstrated by contrast angiography and center-line analysis in 21 (78%) of the 27 formerly hibernating territories. Among these, none had a transmural defect, and 38% had a normal technetium 99m-sestamibi uptake. The four transmural preoperative defects were located in territories without viability. Eight of the 9 territories that were normal at scintigraphy proved to be viable postoperatively. It is concluded that as long as some residual technetium 99m-sestamibi uptake is present, viable myocardium is also present.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7832104     DOI: 10.1016/0002-8703(95)90013-6

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  9 in total

1.  Theoretical model for myocardial functional characterization: application to a group of patients evaluated before and after surgical revascularization.

Authors:  L Bontemps; M Nazzi; M Gabain; O Jegaden; R Felecan; R Itti
Journal:  J Nucl Cardiol       Date:  1998 Mar-Apr       Impact factor: 5.952

2.  Influence of infarct-zone viability detected by rest Tc-99m sestamibi gated SPECT on left ventricular remodeling after acute myocardial infarction treated by percutaneous transluminal coronary angioplasty in the acute phase.

Authors:  Janusz Lipiecki; Florent Cachin; Nicolas Durel; Olivier de Tauriac; Jean Ponsonnaille; Jean Maublant
Journal:  J Nucl Cardiol       Date:  2004 Nov-Dec       Impact factor: 5.952

Review 3.  Are technetium-99m-labeled myocardial perfusion agents adequate for detection of myocardial viability?

Authors:  B Caner; G A Beller
Journal:  Clin Cardiol       Date:  1998-04       Impact factor: 2.882

4.  Dobutamine magnetic resonance imaging as a predictor of myocardial functional recovery after revascularisation.

Authors:  R J Trent; G D Waiter; G S Hillis; F I McKiddie; T W Redpath; S Walton
Journal:  Heart       Date:  2000-01       Impact factor: 5.994

5.  Is the addition of ECG gating to technetium-99m sestamibi SPET of value in the assessment of myocardial viability? An evaluation based on two-dimensional echocardiography following revascularization.

Authors:  P González; T Massardo; A Muñoz; J Jofré; A Rivera; J Yovanovich; E Maiers; F Ayala; P Humeres; A Ramírez; M Arriagada; A Zavala
Journal:  Eur J Nucl Med       Date:  1996-10

6.  Sestamibi SPECT in the detection of myocardial viability in patients with chronic ischemic left ventricular dysfunction: comparison between visual and quantitative analysis.

Authors:  W Acampa; M Petretta; L Florimonte; M S di Santolo; A Cuocolo
Journal:  J Nucl Cardiol       Date:  2000 Sep-Oct       Impact factor: 5.952

7.  Quantitative thallium-201 and technetium 99m sestamibi tomography at rest in detection of myocardial viability in patients with chronic ischemic left ventricular dysfunction.

Authors:  A Cuocolo; W Acampa; E Nicolai; L Pace; M Petretta; M Salvatore
Journal:  J Nucl Cardiol       Date:  2000 Jan-Feb       Impact factor: 5.952

Review 8.  Noninvasive assessment myocardial viability: current status and future directions.

Authors:  Kevin C Allman
Journal:  J Nucl Cardiol       Date:  2013-06-15       Impact factor: 5.952

9.  Prognostic value of nitrate enhanced Tc99m MIBI SPECT study in detecting viable myocardium in patients with coronary artery disease.

Authors:  Magdalena Kostkiewicz; Maria Olszowska; Tadeusz Przewłocki; Piotr Podolec; Wiesława Tracz
Journal:  Int J Cardiovasc Imaging       Date:  2003-04       Impact factor: 2.357

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.